PepGen climbs after $125 mln equity raise for muscle disease drug
** Shares of PepGen PEPG.O up 6.5% at $5.60 premarket on Thurs after $125 mln follow-on priced
** PEPG late Weds sold 25 mln shares at $5
** On Tues, PEPG's stock surged 93% to $4.61, an over seven-month high, after stronger-than-expected mid-stage trial results for its experimental drug, PGN-EDODM1, for myotonic dystrophy type 1 (DM1)
** Stock closed up ~14% at $5.26 on Weds
** Co to use net offering proceeds to fund clinical development of PGN-EDODM1, and for working capital and other general purposes
** Leerink, Stifel and Guggenheim are joint bookrunners; Oppenheimer is a passive bookrunner
** Boston, Massachusetts-based PEPG has ~69.26 mln shares outstanding
** Through Weds, stock down 19% YTD
** 7 of 8 analysts rate the stock "strong buy" or "buy", 1 "hold"; median PT $11, per LSEG data